{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T22:52:19Z","timestamp":1771455139890,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,5,8]],"date-time":"2015-05-08T00:00:00Z","timestamp":1431043200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12885-015-1362-2","type":"journal-article","created":{"date-parts":[[2015,5,7]],"date-time":"2015-05-07T07:13:51Z","timestamp":1430982831000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma"],"prefix":"10.1186","volume":"15","author":[{"given":"Neetu","family":"Kalra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anish","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqiang","family":"Xi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Talarchek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Burkett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria G","family":"Tsokos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanbin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Raffeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markku","family":"Miettinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira","family":"Pastan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph R","family":"Testa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,8]]},"reference":[{"issue":"7","key":"1362_CR1","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/S1470-2045(12)70126-2","volume":"13","author":"A Thomas","year":"2012","unstructured":"Thomas A, Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol. 2012;13(7):e301\u201310.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1362_CR2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1183\/09031936.99.13352799","volume":"13","author":"AM Orengo","year":"1999","unstructured":"Orengo AM, Spoletini L, Procopio A, Favoni RE, De Cupis A, Ardizzoni A, et al. Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis. Eur Respir J. 1999;13(3):527\u201334.","journal-title":"Eur Respir J"},{"issue":"5","key":"1362_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1349-7006.2006.00184.x","volume":"97","author":"N Usami","year":"2006","unstructured":"Usami N, Fukui T, Kondo M, Taniguchi T, Yokoyama T, Mori S, et al. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci. 2006;97(5):387\u201394.","journal-title":"Cancer Sci"},{"issue":"1A","key":"1362_CR4","first-page":"197","volume":"28","author":"M Kobayashi","year":"2008","unstructured":"Kobayashi M, Takeuchi T, Ohtsuki Y. Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status. Anticancer Res. 2008;28(1A):197\u2013208.","journal-title":"Anticancer Res"},{"issue":"6","key":"1362_CR5","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/jnci\/56.6.1251","volume":"56","author":"Y Shimosato","year":"1976","unstructured":"Shimosato Y, Kameya T, Najai K, Hirohashi S, Koide T, Hayashi H, et al. Transplantation of human tumors in nude mice. J Natl Cancer Inst. 1976;56(6):1251\u201360.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"1362_CR6","doi-asserted-by":"publisher","first-page":"e58132","DOI":"10.1371\/journal.pone.0058132","volume":"8","author":"V Relan","year":"2013","unstructured":"Relan V, Morrison L, Parsonson K, Clarke BE, Duhig EE, Windsor MN, et al. Phenotypes and karyotypes of human malignant mesothelioma cell lines. PLoS One. 2013;8(3):e58132.","journal-title":"PLoS One"},{"issue":"21","key":"1362_CR7","first-page":"5547","volume":"54","author":"JQ Cheng","year":"1994","unstructured":"Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomare DA, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 1994;54(21):5547\u201351.","journal-title":"Cancer Res"},{"issue":"24","key":"1362_CR8","doi-asserted-by":"publisher","first-page":"10854","DOI":"10.1073\/pnas.92.24.10854","volume":"92","author":"AB Bianchi","year":"1995","unstructured":"Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A. 1995;92(24):10854\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1362_CR9","first-page":"1227","volume":"55","author":"Y Sekido","year":"1995","unstructured":"Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 1995;55(6):1227\u201331.","journal-title":"Cancer Res"},{"issue":"7","key":"1362_CR10","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43(7):668\u201372.","journal-title":"Nat Genet"},{"issue":"10","key":"1362_CR11","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43(10):1022\u20135.","journal-title":"Nat Genet"},{"issue":"17","key":"1362_CR12","doi-asserted-by":"publisher","first-page":"6953","DOI":"10.1158\/0008-5472.CAN-08-0365","volume":"68","author":"KH Ventii","year":"2008","unstructured":"Ventii KH, Devi NS, Friedrich KL, Chernova TA, Tighiouart M, Van Meir EG, et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res. 2008;68(17):6953\u201362.","journal-title":"Cancer Res"},{"issue":"6","key":"1362_CR13","first-page":"1794","volume":"27","author":"N Kalra","year":"2012","unstructured":"Kalra N, Ashai A, Xi L, Zhang J, Avital I, Raffeld M, et al. Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors. Oncol Rep. 2012;27(6):1794\u2013800.","journal-title":"Oncol Rep"},{"issue":"5","key":"1362_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1177\/153303460800700509","volume":"7","author":"A Mohamedali","year":"2008","unstructured":"Mohamedali A, Lea NC, Feakins RM, Raj K, Mufti GJ, Kocher HM. AKT1 (E17K) mutation in pancreatic cancer. Technol Cancer Res Treat. 2008;7(5):407\u20138.","journal-title":"Technol Cancer Res Treat"},{"issue":"4","key":"1362_CR15","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1182\/blood-2011-09-379339","volume":"119","author":"L Xi","year":"2012","unstructured":"Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood. 2012;119(4):3330\u20132.","journal-title":"Blood"},{"issue":"1","key":"1362_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jmoldx.2010.11.010","volume":"13","author":"Z Su","year":"2011","unstructured":"Su Z, Dias-Santagata D, Duke M, Hutchinson K, Lin YL, Borger DR, et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn. 2011;13(1):74\u201384.","journal-title":"J Mol Diagn"},{"issue":"3","key":"1362_CR17","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S1525-1578(10)60569-7","volume":"7","author":"Q Pan","year":"2005","unstructured":"Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn. 2005;7(3):396\u2013403.","journal-title":"J Mol Diagn"},{"issue":"4","key":"1362_CR18","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/modpathol.2011.184","volume":"25","author":"SR Chowdhuri","year":"2012","unstructured":"Chowdhuri SR, Xi L, Pham TH, Hanson J, Rodriguez-Canales J, Berman A, et al. EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Mod Pathol. 2012;25(4):548\u201355.","journal-title":"Mod Pathol"},{"issue":"6","key":"1362_CR19","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1593\/neo.08336","volume":"10","author":"K Nosho","year":"2008","unstructured":"Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia. 2008;10(6):534\u201341.","journal-title":"Neoplasia"},{"issue":"5","key":"1362_CR20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nm1708","volume":"14","author":"J Li","year":"2008","unstructured":"Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos GM. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med. 2008;14(5):579\u201384.","journal-title":"Nat Med"},{"issue":"12","key":"1362_CR21","first-page":"5151","volume":"32","author":"J Zhang","year":"2012","unstructured":"Zhang J, Qiu S, Zhang Y, Merino M, Fetsch P, Avital I, et al. Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P. Anticancer Res. 2012;32(12):5151\u20138.","journal-title":"Anticancer Res"},{"issue":"3","key":"1362_CR22","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1096\/fj.04-3062fje","volume":"19","author":"W Parson","year":"2005","unstructured":"Parson W, Kirchebner R, M\u00fchlmann R, Renner K, Kofler A, Schmidt S, et al. Cancer cell line identification by short tandem repeat profiling: power and limitations. FASEB J. 2005;19(3):434\u20136.","journal-title":"FASEB J"},{"issue":"2","key":"1362_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/gcc.2870010207","volume":"1","author":"WL Flejter","year":"1989","unstructured":"Flejter WL, Li FP, Antman KH, Testa JR. Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes. Genes Chromosomes Cancer. 1989;1(2):148\u201354.","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"1362_CR24","first-page":"511","volume":"11","author":"S Xio","year":"1995","unstructured":"Xio S, Li D, Vijg J, Sugarbaker DJ, Corson JM, Fletcher JA. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene. 1995;11(3):511\u20135.","journal-title":"Oncogene"},{"issue":"24","key":"1362_CR25","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1093\/jnci\/87.24.1870","volume":"87","author":"RA Kratzke","year":"1995","unstructured":"Kratzke RA, Otterson GA, Lincoln CE, Ewing S, Oie H, Geradts J, et al. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst. 1995;87(24):1870\u20135.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"1362_CR26","first-page":"2108","volume":"9","author":"PB Illei","year":"2003","unstructured":"Illei PB, Rusch VW, Zakowski MF, Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res. 2003;9(6):2108\u201313.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1362_CR27","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/0003-4975(95)00045-M","volume":"59","author":"HI Pass","year":"1995","unstructured":"Pass HI, Stevens EJ, Oie H, Tsokos MG, Abati AD, Fetsch PA, et al. Characteristics of nine newly derived mesothelioma cell lines. Ann Thorac Surg. 1995;59(4):835\u201344.","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"1362_CR28","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","volume":"103","author":"Y Yoshikawa","year":"2012","unstructured":"Yoshikawa Y, Sato A, Tsujimura T, Emi M, Morinaga T, Fukuoka K, et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci. 2012;103(5):868\u201374.","journal-title":"Cancer Sci"},{"issue":"7","key":"1362_CR29","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1136\/jcp.2010.076794","volume":"63","author":"CT Chung","year":"2010","unstructured":"Chung CT, Santos Gda C, Hwang DM, Ludovski O, Pintilie M, Squire JA, et al. FISH assay development for the detection of p16\/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol. 2010;63(7):630\u20134.","journal-title":"J Clin Pathol"},{"issue":"4","key":"1362_CR30","doi-asserted-by":"publisher","first-page":"e18828","DOI":"10.1371\/journal.pone.0018828","volume":"6","author":"DA Altomare","year":"2011","unstructured":"Altomare DA, Menges CW, Xu J, Pei J, Zhang L, Tadevosyan A, et al. Losses of both products of the Cdkn2a\/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. PLoS One. 2011;6(4):e18828.","journal-title":"PLoS One"},{"issue":"19","key":"1362_CR31","first-page":"4297","volume":"56","author":"WC Lee","year":"1996","unstructured":"Lee WC, Balsara B, Liu Z, Jhanwar SC, Testa JR. Loss of heterozygosity analysis defines a critical region in chromosome 1p22 commonly deleted in human malignant mesothelioma. Cancer Res. 1996;56(19):4297\u2013301.","journal-title":"Cancer Res"},{"issue":"1","key":"1362_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s10147-011-0369-1","volume":"17","author":"T Tsujimura","year":"2012","unstructured":"Tsujimura T, Torii I, Sato A, Song M, Fukuoka K, Hasegawa S, et al. Pathological and molecular biological approaches to early mesothelioma. Int J Clin Oncol. 2012;17(1):40\u20137.","journal-title":"Int J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-015-1362-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1362-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1362-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1362-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T12:06:08Z","timestamp":1630584368000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-015-1362-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,8]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1362"],"URL":"https:\/\/doi.org\/10.1186\/s12885-015-1362-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,8]]},"assertion":[{"value":"13 October 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"376"}}